Bristol-Myers Squibb Company (BMY) has been receiving a lot of attention in the market lately. Largely controlled by institutional shareholders, it seems BMY is favored among billionaires as a high growth dividend paying investment. The Company has achieved several FDA approvals for its cancer treatments including Opdivo and Yervoy combination therapy for liver and colorectal cancer. Additionally, their novel drug Breyanzi received EC approval for NHL treatment. Despite some turbulence, with shares trending down by 4.32% on April 9 and a report of a planned cost cut of $2 billion by 2027, many investors remain intrigued. Early FDA approval for their therapeutics and dismissal of a Pomalyst monopoly lawsuit have boosted the company's reputation. Furthermore, the acquisition of cell therapy partner 2seventy bio for $286M and beating Q4 earnings estimates underpin confidence. However, some caution remains due to recent stock undervaluation concerns and near-term impact of generics on their 2025 sales forecast. Despite the apprehension, the stock remains attractive with its high-dividend yield.
